Pharmaceutical price regulation has been used in major pharmaceutical markets to correct market imperfections and contain rising healthcare costs. But regulations can affect the adoption of innovations, especially in highly regulated industries such as the pharmaceutical industry where products and processes are protected by intellectual property rights.
Does price regulation affect the adoption of new pharmaceuticals?
Joan Costa-i-Font, Nebibe Varol, Alistair McGuire, 8 July 2011
Direct-to-consumer advertising in pharmaceutical markets: Effects on demand and prices
Dhaval Dave, 3 June 2010
Direct-to-consumer advertising (DTCA) by pharmaceutical companies has always been somewhat controversial, with the US and New Zealand being the only two developed countries that allow such promotion. Direct-to-consumer advertisements in the US are broadcast on television and radio, are displayed on billboards, appear in the pages of magazines and newspapers, and are on the internet.
Pharmaceutical innovation and the longevity of Australians: A first look
Frank R. Lichtenberg, Gautier Duflos, 29 June 2008
Some critics of the pharmaceutical industry (e.g. Angell 2005) claim that most of the new drugs launched by drug companies cost much more than older drugs but are no more effective. If this were the case, then the launch and utilisation of new drugs would not have much impact on health and longevity.
Can the US complain about "free-riding" regulation in pharmaceuticals by other countries?
Antonio Cabrales, 21 June 2007
A large generation of baby boomers reaching retirement age, and a steadily decreasing dependency ratio (number of working people per retiree) in most developing countries (and not too far in the future in China and elsewhere) make the economics of healthcare an increasingly important topic in the public arena. One key issue in this area is the price of pharmaceutical products.
- Fiscal consolidation: At what speed?Blanchard, Leigh
- Escaping liquidity traps: Lessons from the UK’s 1930s escapeCrafts
- The lessons of the North Atlantic crisis for economic theory and policyStiglitz
- Helicopter money as a policy optionReichlin, Turner, Woodford
- The case for 4% inflationBall
- A tale of two depressions: What do the new data tell us? February 2010 updateEichengreen, O’Rourke
- Educated in America: College graduates and high school dropoutsHeckman, LaFontaine
- Eurozone breakup would trigger the mother of all financial crisesEichengreen
- Debt, deleveraging, and the liquidity trap: A new modelKrugman
- Panic-driven austerity in the Eurozone and its implicationsDe Grauwe, Ji
Reichlin, Baldwin, 14 April 2013
Reichlin, Turner, Woodford
CEPR Policy Research
- The "Greatest" Carry Trade Ever? Understanding Eurozone Bank RisksAcharya, Steffen
- Political Credit Cycles: The Case of the Euro ZoneFernández-Villaverde, Garicano, Santos
- Winning by Losing: Incentive Incompatibility in Multiple QualifiersDagaev, Sonin
- Income and schoolingBrückner, Gradstein
- Monetary Policy and Rational Asset Price BubblesGalí
- How the EZ crisis is permanently changing EU institutionsMicossi
- WTO 2.0: Global governance of supply-chain tradeBaldwin
- Is US economic growth over? Faltering innovation confronts the six headwindsGordon
- The economic crisis: How to stimulate economies without increasing public debtWood
- Austerity: Too Much of a Good Thing?Corsetti